Tyrosinemia type I, the drug that rewrote the prognosis

In 1991, the median survival of a child with tyrosinemia type I was about 5 years if the disease presented in infancy. Death came from liver failure, hepatocellular carcinoma, or kidney failure. Liver transplantation was the only intervention that altered the course, and most children did not survive long enough to receive one.

In 1992, Sven Lindstedt and colleagues in Sweden published a paper in The Lancet describing the use of a herbicide-derived compound, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, NTBC, in five children with tyrosinemia type I. The drug worked. NTBC, later named nitisinone and approved by the FDA as Orfadil in 2002, reset the prognosis of tyrosinemia type I from a near-uniformly fatal disease in early childhood to a chronic condition managed across decades.

What tyrosinemia type I is

Tyrosinemia type I is an autosomal recessive disorder of tyrosine catabolism. The enzyme fumarylacetoacetate hydrolase, FAH, encoded by FAH on chromosome 15q25, catalyzes the final step of tyrosine breakdown. Without FAH activity, the upstream metabolites maleylacetoacetate and fumarylacetoacetate accumulate in the liver and kidney. These metabolites alkylate proteins and DNA. The clinical consequence is severe liver dysfunction, renal tubular dysfunction (Fanconi syndrome), and progressive risk of hepatocellular carcinoma. Succinylacetone, a downstream metabolite, accumulates in blood and urine and serves as the diagnostic marker.

The acute form presents in the first months of life with hepatomegaly, coagulopathy out of proportion to other liver function abnormalities, hypoglycemia, ascites, and failure to thrive. Without treatment, hepatic decompensation or sepsis from coagulopathy is fatal in months. The chronic form presents later with progressive liver disease, renal tubulopathy producing hypophosphatemic rickets, and porphyric crises that mimic acute intermittent porphyria. Hepatocellular carcinoma develops in a substantial fraction of unscreened, untreated, or transplant-only-managed cohorts.

The condition is rare worldwide. Reported live-birth incidence is roughly 1 in 100,000 to 1 in 120,000 in unselected populations. Founder effects produce dramatically higher rates in specific regions: roughly 1 in 1,500 in the Saguenay-Lac-Saint-Jean region of Quebec, where a population-genetics study documented the founder allele to a single 17th-century settler.

Detection

Newborn screening for tyrosinemia type I uses succinylacetone, SUAC, on the dried blood spot. The marker is highly specific for FAH deficiency. Tyrosine elevation alone is not specific, because tyrosine can be elevated in transient tyrosinemia of the newborn, in late preterm infants, and in other tyrosinemia subtypes (II and III) that have a different clinical course. Most US states screen using SUAC; programs that historically screened on tyrosine alone have transitioned to SUAC-based screening as the assays became standard.

Confirmation uses plasma amino acids (with elevated tyrosine and methionine), urine organic acids (with elevated SUAC and tyrosine metabolites), elevated alpha-fetoprotein in many cases, and FAH gene sequencing.

What NTBC does

NTBC inhibits 4-hydroxyphenylpyruvate dioxygenase, the second enzyme in the tyrosine catabolic pathway, two steps upstream of FAH. By blocking the pathway upstream, NTBC prevents the accumulation of the toxic downstream metabolites. The biochemical consequence is that tyrosine itself accumulates, which is why NTBC therapy must be paired with a tyrosine and phenylalanine restricted diet.

NTBC was developed in the 1980s as a herbicide. The connection to tyrosinemia came through the recognition that the same enzyme inhibition that produced bleached weeds in plants would prevent toxic-metabolite accumulation in children with FAH deficiency. The Swedish Phase 1 results, published in 1992, showed rapid biochemical correction. Long-term follow-up data, the NTBC Study, demonstrated dramatic survival improvement and reduction in hepatocellular carcinoma when treatment was started early.

What management looks like

Standard of care is lifelong NTBC plus a tyrosine and phenylalanine restricted diet using medical formula free of those amino acids combined with measured natural protein. NTBC dosing is titrated to clinical and biochemical response, typically 1 to 2 mg per kg per day in divided doses. Liver and renal function, alpha-fetoprotein, plasma amino acids including tyrosine, and urine SUAC are monitored.

Hepatocellular carcinoma surveillance includes alpha-fetoprotein measurement and liver imaging at intervals determined by age and historical exposure. Children identified by newborn screening and started on NTBC within the first weeks of life have markedly lower hepatocellular carcinoma rates than children diagnosed clinically after liver disease has developed.

Liver transplantation, the historical mainstay of treatment, has shifted to a salvage role. Transplant is reserved for children who develop hepatocellular carcinoma despite NTBC, who have advanced cirrhosis at diagnosis, or who do not respond adequately to medical therapy. The shift in role is one of the cleanest illustrations of what a disease-specific small molecule can do for a metabolic disorder.

What this looks like for a family

A baby is born and the heel-prick is sent. On day 4, the metabolic clinic calls about an elevated SUAC. On day 5, the family meets the metabolic dietitian and the pediatric hepatologist. NTBC is started. The diet is started. Alpha-fetoprotein is checked at baseline and tracked. Liver and kidney function are checked at baseline and tracked. The family learns the medication schedule, the food list, the sick-day plan, the surveillance schedule that will continue for life.

That child grows up. Hepatocellular carcinoma surveillance continues. Tyrosine restriction continues. NTBC continues. Pregnancy planning, eventual transition to adult metabolic services, eventual decisions about long-term cancer surveillance frequency, all of those questions are now decades away rather than weeks. The disease is the same disease. The drug rewrote the prognosis.